Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Brian Gadbaw"'
Autor:
Joe McDonough, G. Lesa, Franca Ligas, Miguel Rivera, Ira Jacobs, Andrew D.J. Pearson, Malcolm A. Smith, Maureen Hattersley, Dominik Karres, Aundrietta D. Duncan, Nada Jabado, Daniel D. De Carvalho, Koen Norga, Peter C. Adamson, Donna Ludwinski, Gregory H. Reaman, Brian Gadbaw, Elizabeth Fox, Samuel C. Blackman, Mark W. Kieran, Gilles Vassal, Christian Baumann, Vickie Buenger, Delphine Heenen, Scott A. Armstrong, Michael J. Kelly, Amy Barone, Adrian Senderowicz, Franck Bourdeaut, Martha Donoghue, Tilmann Taube, Peter T.C. Ho, Lynley V. Marshall, Patrick A. Brown, Michael L. Meyers, Kimberly Stegmaier, Zariana Nikolova, Susan L. Weiner
Publikováno v:
European Journal of Cancer. 139:135-148
The fifth multistakeholder Paediatric Strategy Forum focussed on epigenetic modifier therapies for children and adolescents with cancer. As most mutations in paediatric malignancies influence chromatin-associated proteins or transcription and paediat
Autor:
Wen Zhou, Brian Gadbaw, Savita Bharathy, Taoufik Ouatas, Andrew Avigdor Butler, Felix Huth, Vassilios Aslanis, Kenichi Umehara
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:749-757
Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure relative to a single pathway inhibition of CYP3A4 or CYP2C9. The magnitude of this interacti
Autor:
Andrew Dj, Pearson, Kimberly, Stegmaier, Franck, Bourdeaut, Gregory, Reaman, Delphine, Heenen, Michael L, Meyers, Scott A, Armstrong, Patrick, Brown, Daniel, De Carvalho, Nada, Jabado, Lynley, Marshall, Miguel, Rivera, Malcolm, Smith, Peter C, Adamson, Amy, Barone, Christian, Baumann, Samuel, Blackman, Vickie, Buenger, Martha, Donoghue, Aundrietta D, Duncan, Elizabeth, Fox, Brian, Gadbaw, Maureen, Hattersley, Peter, Ho, Ira, Jacobs, Michael J, Kelly, Mark, Kieran, Giovanni, Lesa, Franca, Ligas, Donna, Ludwinski, Joe, McDonough, Zariana, Nikolova, Koen, Norga, Adrian, Senderowicz, Tilmann, Taube, Susan, Weiner, Dominik, Karres, Gilles, Vassal
Publikováno v:
European journal of cancer
The fifth multistakeholder Paediatric Strategy Forum focussed on epigenetic modifier therapies for children and adolescents with cancer. As most mutations in paediatric malignancies influence chromatin-associated proteins or transcription and paediat
Autor:
Michael C. Arbushites, Madan Jagasia, Brian Gadbaw, Nikolas von Bubnoff, Patricia Delaite, Robert Zeiser
Publikováno v:
Immunotherapy. 10:391-402
For patients with hematologic malignancies and disorders, allogeneic hematopoietic stem cell transplantation offers a potentially curative treatment option. Many patients develop graft-versus-host disease (GVHD), a serious complication and leading ca
Autor:
Martin Griesshammer, Srdan Verstovsek, Julian Perez Ronco, Jingjin Li, Mahmudul Khan, Brian Gadbaw, Hui-Ling Zhen, Francesco Passamonti, Simon Durrant, Paola Guglielmelli, Jean-Jacques Kiladjian, Tamás Masszi, Güray Saydam, Mark M. Jones
Publikováno v:
Annals of Hematology. 97:617-627
WOS: 000426644800007
PubMed ID: 29396713
Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and improving po
PubMed ID: 29396713
Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and improving po
Autor:
Kyosuke Yamauchi, Keita Kirito, Masayuki Hino, Taro Amagasaki, Kazuo Ito, Kenshi Suzuki, Koichi Miyamura, Brian Gadbaw, Hiroshi Handa, Shinichiro Okamoto, Masahiro Takeuchi
Publikováno v:
International Journal of Hematology. 107:173-184
Ruxolitinib, a potent JAK1/JAK2 inhibitor, was found to be superior to the best available therapy (BAT) in controlling hematocrit, reducing splenomegaly, and improving symptoms in the phase 3 RESPONSE study of patients with polycythemia vera with spl
Autor:
Srdan Verstovsek, Timothy Burn, Jean-Jacques Kiladjian, Ahmad Naim, Alessandro M. Vannucchi, Brian Gadbaw, Mahtab Marker, Martin Griesshammer, Paola Guglielmelli, Dilan Paranagama
Publikováno v:
Annals of Hematology
In patients with polycythemia vera (PV), an elevated JAK2 p.V617F allele burden is associated with indicators of more severe disease (e.g., leukocytosis, splenomegaly, and increased thrombosis risk); however, correlations between allele burden reduct
Autor:
Antonis Kattamis, Norbert Hollaender, Noppadol Siritanaratkul, Elena Cassinerio, Aurelio Maggio, Stefano Rivella, Bruyère Mahuzier, Ali T. Taher, Yesim Aydinok, Zeynep Karakas, Brian Gadbaw
Publikováno v:
Blood. 131:263-265
In beta-thalassemia, the mechanism driving ineffective erythropoiesis (IE) is insufficiently understood. We analyzed mice affected by beta-thalassemia and observed, unexpectedly, a relatively small increase in apoptosis of their erythroid cells compa
Autor:
Margaret Squier, Brian Gadbaw, Monica M. Mita, Margaret M. Woo, Sofia Paul, Sunil Sharma, H. Miles Prince, Joachim Beck
Publikováno v:
Investigational New Drugs. 31:974-985
Purpose Panobinostat, a pan-deacetylase inhibitor, is a promising anti-cancer agent that increases acetylation of proteins associated with growth and survival pathways of malignant cells. The primary objective of this phase I dose-escalation study wa
Autor:
Heidi Schalch, Brian Gadbaw, KyungMann Kim, Jacek Gan, Jacquelyn A. Hank, Jordan Kostlevy, Stephen D. Gillies, Mark R. Albertini, Jennifer Haldeman, Jens C. Eickhoff, Paul M. Sondel
Publikováno v:
Cancer Immunology, Immunotherapy. 61:2261-2271
Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m2/day. In this phase II study, 14 patients with measurable metastatic melanoma were schedu